0 results for 'Novo Nordisk A/S'
Job-Hopping Biotech Lawyers Losing Leverage as Funding Challenges Chill Sector
"Companies are not hiring at the same pace, for sure, and searches are taking longer to close, as companies are being a lot more introspective on who to hire," said Deb Thompson, a Major, Lindsey & Africa partner.Novo Nordisk Sues Weight Loss Company for Alleged False Statements About Ozempic, Other Drugs
This suit was surfaced by Law.com Radar. Read the complaint here.Covington Goes to Boston, as More Big Pharma Clients Relocate to City
The new office will be anchored by Megan Gates, who was chair of Mintz's corporate and securities practice.An Early Batch of Litigator of the Week Shout Outs—With a Twist
Here's a look at the big wins that came in during the Litigator of the Week cycle that passed while we were out.Fenwick, With New Client Capabilities, Grew Revenue Nearly 4% as Profits Inched Down
Revenue grew to $750.4 million, thanks to new regulatory capabilities and intellectual property growth, while profits fell 1.4% at Fenwick in 2022.View more book results for the query "Novo Nordisk A/S"
After Helping Sell Last Employer for $16B, Attorney Takes Legal Reins of Nerve-Repair Company
Axogen has hired Marc Began as general counsel. He most recently was legal chief of the medical device company Abiomed, which Johnson & Johnson bought for $16 billion.Eli Lilly's Insulin Price Cut Not Likely to Extricate It From Legal Morass
"If a company has acquired or maintained monopoly power through anticompetitive means, they're liable under the antitrust laws whether or not they're exploiting their monopoly power by charging monopoly prices," said Daniel Crane, a professor at the University of Michigan Law School.SCOTUS Bound? After Appellate Ruling, What's Next in 340B Drug Discount Cases?
The statutory question at the center of the appeals could create a circuit split that brings the issue to the U.S. Supreme Court, said one court watcher.After 3rd Circ. Ruling, Are 340B Drug Discount Cases SCOTUS Bound?
The statutory question at the center of the appeals could create a circuit split that brings the issue to the U.S. Supreme Court, said one court watcher.3rd Circuit Sides With Drug Manufacturers in 340B Contract Pharmacy Case
"Legal duties do not spring from silence. Congress never said that drug makers must deliver discounted Section 340B drugs to an unlimited number of contract pharmacies," Judge Stephanos Bibas wrote. "So by trying to enforce that supposed requirement, the government overstepped the statute's bounds. And HHS did not violate the APA by purporting to withdraw the proposed ADR Rule before later finalizing it."Corporate Transparency Act Resource Kit
Brought to you by Wolters Kluwer
Download Now
Revenue, Profit, Cash: Managing Law Firms for Success
Brought to you by Juris Ledger
Download Now
Law Firm Operational Considerations for the Corporate Transparency Act
Brought to you by Wolters Kluwer
Download Now
The Ultimate Guide to Remote Legal Work
Brought to you by Filevine
Download Now